Format

Send to

Choose Destination
Immunotherapy. 2016 Jul;8(8):847-52. doi: 10.2217/imt-2015-0023.

Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia.

Author information

1
Research Assistant, Hematology Department of Medicine, University of Arizona, AZ, USA.
2
Department of Medicine, University of Arizona, AZ, USA.
3
Department of Pathology, University of Arizona, AZ, USA.
4
Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, MN, USA.
5
Division of Hematology, Oncology, Blood & Marrow Transplantation, University of Arizona, Tucson, AZ 86721, USA.

Abstract

Post-stem cell transplantation (SCT) relapsed acute lymphoblastic leukemia (ALL) has extremely poor prognosis with median survival of less than 1 year. Donor lymphocyte infusion, second transplantation, chemotherapy or cytokine treatment have been tried as a salvage regimen without significant clinical benefit. Recently, blinatumomab, a bispecific monoclonal antibody targeting CD3-expressing T cells and CD19-expressing B-cell lineage malignant cells demonstrated promising outcomes in relapsed/refractory ALL patients. Literature on blinatumomab use in biphenotypic ALL along with Philadelphia chromosome positive (Ph(+)) ALL is limited. We report a case of post-SCT relapsed CD19 expressing biphenotypic lymphoblastic leukemia patient who achieved complete remission after blinatumomab treatment and has lasting remission for 1 year.

KEYWORDS:

Blinatumomab; CD19; biphenotypic acute leukemia

PMID:
27381683
DOI:
10.2217/imt-2015-0023
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center